Mast Cells: A New Target for Diabetic Nephropathy

  • Jonathan Kopel Texas Tech University Health Sciences Center


Diabetes remains a mounting health burden as more patients with chronic and uncontrolled diabetes develop progressively worse complications requiring extensive medical and surgical interventions. In many instances, chronically uncontrolled diabetes can injure the kidneys leading to diabetic nephropathy (DN). Among diabetics, DN patients have a worse prognosis and survival with many chronic kidney disease and end-stage renal disease (ESRD), which increases the demand for dialysis and surgical intervention. Despite several available pharmacological treatments, most fail to improve survival among DN patients. As a result, new pharmaceutical regiments for managing DN is critically needed. In recent years, pharmaceutical therapies targeting mast cells in DN have shown great potential to reduce renal inflammation and induce remodeling of damaged kidney structures. Further double-blind clinical trials are needed to evaluate the efficacy and safety of mast cell stabilizers among DN patients